Yahoo Finance IgA Nephropathy Clinical Trials Pipeline Analysis: 30+ Companies are Working to Improve the Treatment Space | DelveInsight
DelveInsight’s IgA nephropathy pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for IgA nephropathy treatment.
New York, USA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- IgA Nephropathy Clinical Trials Pipeline Analysis: 30+ Companies are Working to Improve the Treatment Space | DelveInsight
DelveInsight’s IgA nephropathy pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for IgA nephropathy treatment.
DelveInsight’s 'IgA Nephropathy Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline IgA nephropathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the IgA nephropathy pipeline domain.
Key Takeaways from the IgA Nephropathy Pipeline Report
DelveInsight’s IgA nephropathy pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for IgA nephropathy treatment.
Key IgA nephropathy companies such as Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, and others are evaluating new drugs for IgA nephropathy to improve the treatment landscape.
Promising IgA nephropathy pipeline therapies in various stages of development include BION-1301, Telitacicept, LNP023, HR19042, IONIS-FB-LRx, Atacicept, Atrasentan, AT-1501, SHR-2010, OMS721, Sibeprenlimab, Cemdisiran, Felzartamab, ADR-001, Ravulizumab, ALXN2050, APL-2, ARO-C3, Mezagitamab, Sparsentan, BCX9930, TST 004, AP 305, AP 308, DM199, KP104, ALPN-303, and others.
On November 7, 2022, Ionis Pharmaceuticals, Inc. presented positive results from a Phase 2 clinical study of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN). Results from the study were presented in a poster session at the American Society of Nephrology's (ASN) Kidney Week 2022.
On November 05, 2022, Vera Therapeutics, Inc. announced new clinical data presented on the Company’s two product candidates, atacicept in immunoglobulin A nephropathy (IgAN) and MAU868 in kidney transplant. These data were presented in poster and oral presentations, respectively, at the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting, held November 3-6, 2022, in Orlando, Florida.
In October 2022, Transcenta Holding Limited announced that TST004, its best-in-class, humanized monoclonal antibody targeting MASP2, had received IND clearance from the U.S. Food and Drug Administration (FDA). MASP2, mannose-binding protein-associated serine protease 2, is a key enzyme in the lectin pathway initiation of complement activation. Studies have shown that lectin pathway activation contributes to multiple human diseases such as immunoglobulin A nephropathy (IgAN), hematopoietic stem-cell transplantation–associated thrombotic microangiopathy (HSCT-TMA). Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.
In September 2022, Eledon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared the company's Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).
In August 2022, Alnylam Pharmaceuticals, Inc. announced positive results from a Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, in development in collaboration with Regeneron Pharmaceuticals for the treatment of adult patients with immunoglobulin A nephropathy (IgAN). The results were presented at the 18th European Meeting on Complement in Human Disease (EMCHD), being held in Bern, Switzerland, on August 26-28.
In August 2022, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).
In July 2022, Chinook Therapeutics, Inc. announced the European Commission had granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). The decision follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).
Request a sample and discover the recent advances in IgA nephropathy treatment drugs @ IgA Nephropathy Pipeline Report
The IgA nephropathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage IgA nephropathy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the IgA nephropathy clinical trial landscape.
IgA Nephropathy Overview
IgA nephropathy, also known as Berger's disease, is a kidney disease in which IgA deposits accumulate in the kidneys, causing inflammation and damage to kidney tissues. IgA is an antibody, which is a protein produced by the immune system to defend the body against foreign substances such as bacteria or viruses. The IgA nephropathy causes are not known.
Hematuria and proteinuria, ankle swelling, and high blood pressure are the most common IgA nephropathy symptoms. Some of the procedures used for IgA nephropathy diagnosis include urine tests, blood tests, Glomerular Filtration rate, and kidney biopsy. There is no cure for IgA nephropathy, but treatments can help prevent further kidney damage.
Find out more about IgA nephropathy treatment drugs @ Drugs for IgA Nephropathy Treatment
A snapshot of the IgA Nephropathy Pipeline Drugs mentioned in the report:
Drugs | Company | Phase | MoA | RoA |
Sparsentan | Travere Therapeutics | Pre-registration | Angiotensin type 1 receptor antagonist | Oral |
Atrasentan | Chinook Therapeutics | Phase III | Endothelin A receptor antagonist | Oral |
LNP023 | Novartis Pharmaceuticals | Phase III | Complement factor B inhibitor | Oral |
HR19042 | Jiangsu HengRui Medicine Co., Ltd. | Phase II | NA | Oral |
ADR-001 | Rohto Pharmaceutical Co., Ltd. | Phase I | Cell replacement | Intravenous |
Learn more about the emerging IgA nephropathy pipeline therapies @ IgA Nephropathy Clinical Trials
IgA Nephropathy Therapeutics Assessment
The IgA nephropathy pipeline report proffers an integral view of IgA nephropathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the IgA Nephropathy Pipeline Report
Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
Therapeutics Assessment By Mechanism of Action: Endothelin A receptor antagonists, Angiotensin type 1 receptor antagonists, Bacteria replacements, Gastrointestinal microbiome modulators, Opioid kappa receptor antagonists, Opioid mu receptor agonists, Serotonin 3 receptor antagonists
Key IgA Nephropathy Companies: Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, and others.
Key IgA Nephropathy Pipeline Therapies: BION-1301, Telitacicept, LNP023, HR19042, IONIS-FB-LRx, Atacicept, Atrasentan, AT-1501, SHR-2010, OMS721, Sibeprenlimab, Cemdisiran, Felzartamab, ADR-001, Ravulizumab, ALXN2050, APL-2, ARO-C3, Mezagitamab, Sparsentan, BCX9930, TST 004, AP 305, AP 308, DM199, KP104, ALPN-303, and others.
Dive deep into rich insights for new drugs for IgA nephropathy treatment; visit @ IgA Nephropathy Drugs
Table of Contents
1. | IgA Nephropathy Pipeline Report Introduction |
2. | IgA Nephropathy Pipeline Report Executive Summary |
3. | IgA Nephropathy Pipeline: Overview |
4. | Analytical Perspective In-depth Commercial Assessment |
5. | IgA Nephropathy Clinical Trial Therapeutics |
6. | IgA Nephropathy Pipeline: Late Stage Products (Pre-registration) |
7. | IgA Nephropathy Pipeline: Late Stage Products (Phase III) |
8. | IgA Nephropathy Pipeline: Mid Stage Products (Phase II) |
9. | IgA Nephropathy Pipeline: Early Stage Products (Phase I) |
10. | IgA Nephropathy Pipeline Therapeutics Assessment |
11. | Inactive Products in the IgA Nephropathy Pipeline |
12. | Company-University Collaborations (Licensing/Partnering) Analysis |
13. | Key Companies |
14. | Key Products in the IgA Nephropathy Pipeline |
15. | Unmet Needs |
16. | Market Drivers and Barriers |
17. | Future Perspectives and Conclusion |
18. | Analyst Views |
19. | Appendix |
For further information on the IgA nephropathy pipeline therapeutics, reach out @ IgA Nephropathy Medications
Related Reports
IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IgA nephropathy companies including Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics, among others.
IgA Nephropathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted IgA nephropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute kidney injury companies, including Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Pharming Technologies, among others.
Acute Kidney Injury Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key acute kidney injury companies, including Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Pharming Technologies, among others.
Acute Kidney Injury Epidemiology Forecast
Acute Kidney Injury Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted acute kidney injury epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Kidney Disease Pipeline
Chronic Kidney Disease Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key chronic kidney disease companies, including Bayer, AstraZeneca, Celgene, Ipsen, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight
Related Healthcare Blogs
IgA Nephropathy Market Outlook
IgA Nephropathy Pipeline Assessment
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
